

EVEKEO (amphetamine sulfate)

Diagnoses Considered for Coverage:

- Narcolepsy
- Attention Deficit Hyperactivity Disorder (ADHD)
- Obesity

Coverage Criteria:

For diagnoses listed above:

- Dose does not exceed 60 mg per day, **and**
- Inadequate response or intolerable side effect with one alternative immediate-release stimulant agent including:
 - amphetamine/dexamphetamine tablet (Adderall)
 - dexamethylphenidate tablet (Focalin)
 - methylphenidate chew tablet (Methylin)
 - methylphenidate tablet (Ritalin)

For brand-name Brand:

- Meets above criteria for generic, **and**
- Allergic or intolerable side effect to the generic formulation.

Coverage Duration: Length of benefit

Effective: 11/01/2018